BACKGROUND: Aging is a complex biological process marked by the decline of physiological functions and heightened susceptibility to chronic illnesses, notably cardiometabolic disorders. Ceramides (Cer) are lipid derivatives linked to aging and metabolic diseases. Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i), widely used in managing type 2 diabetes, have an unclear impact on aging biomarkers and Cer profiles. OBJECTIVE: This study explored the association between SGLT2i use, plasma Cer levels (CerC16:0, CerC18:0, CerC22:0, CerC24:0, and CerC24:1), and aging biomarkers-Human Insulin-Like Growth Factor 1 (IGF-1), mammalian target of rapamycin (mTOR), 5-Methylcytosine (5MC), and Human H2AFX (Histone H2AX) in patients with type 2 diabetes mellitus (T2DM). METHODS: In this retrospective study, 95 participants were divided into three groups: patients on SGLT2i (nâ=â34), patients on non-SGLT2i anti-diabetic treatments (nâ=â36), and healthy controls (nâ=â25). Plasma Cer and aging biomarkers were quantified using Liquid Chromatography with tandem mass spectrometry (LC-MS-MS) and ELISA, respectively. Principal component analysis (PCA) assessed group-based clustering, while ANCOVA evaluated group differences with confounder adjustment. RESULTS: SGLT2i-treated patients showed significantly lower CerC16:0, CerC22:0, and CerC24:1 levels (pâ<â0.01) and decreased 5MC and H2AX (pâ<â0.05) compared to non-SGLT2i patients. IGF-1 was significantly elevated in the SGLT2i group (pâ<â0.01), suggesting a possible protective effect on metabolic health. PCA distinguished control from diabetic groups but revealed overlap between SGLT2i and non-SGLT2i groups. CONCLUSION: Beyond glucose control, SGLT2i may improve plasma Cer and aging markers in diabetic patients, supporting their broader therapeutic potential in aging and age-related diseases. Further large-scale studies are warranted to confirm these effects and underlying mechanisms.
Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control.
钠-葡萄糖协同转运蛋白-2抑制剂对2型糖尿病患者衰老生物标志物和血浆神经酰胺水平的影响:超越血糖控制
阅读:6
作者:Shalaby Youssef M, Nakhal Mohammed Moutaz, Afandi Bachar, Al-Zohily Bashar, Majed Lina, Kumar Kukkala Kiran, Emerald Bright Starling, Sadek Bassem, Akour Amal, Akawi Nadia
| 期刊: | Annals of Medicine | 影响因子: | 4.300 |
| 时间: | 2025 | 起止号: | 2025 Dec;57(1):2496795 |
| doi: | 10.1080/07853890.2025.2496795 | 研究方向: | 神经科学 |
| 疾病类型: | 糖尿病 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
